false 0001656634 0001656634 2021-08-17 2021-08-17





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 17, 2021



Gritstone bio, Inc.

(Exact name of registrant as specified in its charter)




Delaware   001-38663   47-4859534

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification Number)

5959 Horton Street, Suite 300

Emeryville, California 94608

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (510) 871-6100



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, par value $0.0001   GRTS   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 8.01

Other Events.

On August 17, 2021, Gritstone bio, Inc. (the “Company” or “Gritstone”) announced that it entered into a funding agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) for up to $20.6 million to advance the development of Gritstone’s CORAL COVID-19 vaccine program with an initial focus in South Africa. Under the terms of the agreement, CEPI will fund a multi-arm Phase I study evaluating the CORAL program’s SAM vaccine in naïve, convalescent, and HIV positive patients. The funding will also support pre-clinical studies, scale-up and formulation development to enable more stable drug product.

A copy of the press release with the foregoing announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.


Item 9.01

Financial Statements and Exhibits.





99.1    Press Release dated August 17, 2021
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: August 17, 2021     By:  

/s/ Andrew Allen

      Andrew Allen
      President and Chief Executive Officer
EX-99.1 2 d111789dex991.htm EX-99.1 EX-99.1

Exhibit 99.1



Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program (CORAL) Against SARS-CoV-2 Variants of Concern



CEPI to fund Gritstone’s work on second-generation vaccines against SARS-CoV-2, the virus causing COVID-19, including a clinical trial in South Africa and manufacturing optimization



Gritstone’s second-generation vaccines include self-amplifying mRNA (SAM) to deliver multiple antigens (spike protein plus additional sequence from non-spike genes) providing the potential for deep, broad, and durable immunity against SARS-CoV-2 variants



Gritstone’s CORAL Phase 1 program – which includes the CEPI-funded trial—is establishing optimal dosing and antigenic content in young individuals, the elderly, the previously vaccinated, and the immunocompromised, including people living with HIV

EMERYVILLE, CALIF. – August 17, 2021 (GLOBE NEWSWIRE) – Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the company entered into a funding agreement of up to $20.6 million with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of Gritstone’s CORAL COVID-19 vaccine program with an initial focus in South Africa.

“COVID-19 variants are already rendering some of our vaccines less effective, so it is critical that we don’t let our guard down: we must continue to invest in critical vaccine R&D if we are to stay one step ahead of this deadly virus,” said Richard Hatchett, M.D., CEO of CEPI. “CEPI is planning for the longer-term management of COVID-19 by investing in vaccines to address the threat of variants, and I’m pleased to work with Gritstone to advance the development of this innovative vaccine candidate which can be made globally accessible through COVAX if it is proven to be safe and effective.”

“Our unique approach combines our self-amplifying mRNA platform with a broad set of viral antigens beyond spike intended to drive robust and durable immune responses comprising both neutralizing antibodies and CD8+ T cells. With this unique antigenic breadth, our CORAL vaccine may offer protection against emerging spike variants of SARS-CoV-2 that appear challenging for first generation vaccines,” said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone. “We are honored to be supporting CEPI in their mission to help find new vaccine solutions to battle this deadly virus on a global scale and help prevent current and perhaps future COVID outbreaks.”

Professor Shabir Madhi, dean of the Faculty of Health Sciences and professor of vaccinology at the University of the Witwatersrand, Johannesburg, South Africa and a member of the WHO Strategic Advisory Group of Experts on Immunization (SAGE) commented, “The ongoing mutations in SARS-CoV-2 leading to increased transmissibility and relative immune evasion from most first generation COVID-19 vaccines that primarily target the spike protein, call for alternate approaches aimed at driving CD8+ immunity against spike and more conserved epitopes. This could assist in reducing both infectiousness of breakthrough cases and overall virus transmission.” Professor Mahdi will lead the Gritstone clinical trial in South Africa.

Under the terms of the agreement, CEPI will fund a multi-arm Phase 1 study evaluating the CORAL program’s SAM vaccine in naïve, convalescent, and HIV+ patients. The funding will also support pre-clinical studies, scale-up and formulation development to enable more stable drug product. The study will evaluate two different SAM vaccine constructs that each target both the spike protein and other SARS-CoV-2 targets and are designed to drive both robust B and T cell immune responses. The trial is expected to initiate before the end of 2021.

CEPI is committed to global equitable access to COVID-19 vaccines so, through this agreement, CEPI and Gritstone bio have agreed that this vaccine candidate will be made available to the COVAX Facility for procurement and allocation, if proven to be safe and effective. The COVAX Facility aims to deliver equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate.

About the CORAL Program

Gritstone’s CORAL program is a second-generation SARS-CoV-2 vaccine platform delivering spike and additional SARS-CoV-2 T cell epitopes, offering the potential for deep, broad, and durable protection against SARS-CoV-2 variants. Delivery vectors can comprise a chimpanzee adenovirus, self-amplifying mRNA or both. The program is supported by several key relationships: La Jolla Institute for Immunology, Bill & Melinda Gates Foundation, National Institute of Allergy and Infectious Disease (NIAID), and the Coalition for Epidemic Preparedness Innovations (CEPI). A Phase 1 clinical trial is currently being sponsored by NIAID examining the reactogenicity and immunogenicity of CORAL in healthy volunteers and as a booster for previously vaccinated volunteers. Gritstone is sponsoring and conducting its own Phase 1 studies in select populations, which are anticipated to begin before the end of 2021. Together with the CEPI supported study, this set of clinical trials will test four different vaccine candidates and establish optimal dosing and antigenic content for the CORAL program in young individuals, the elderly, the previously vaccinated, and the immunocompromised.

About Gritstone

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary AI -based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop, manufacture, and deliver selected antigens to the patient’s immune system to drive the destruction of tumors or virally-infected cells. . The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI) and through a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. For more information, please visit gritstone.com.

Gritstone Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone’s therapeutic programs; the advancements in the company’s ongoing clinical trials; the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone’s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone’s most recent Quarterly Report on Form 10-Q filed on August 5, 2021 and any current and periodic reports filed with the Securities and Exchange Commission.

EX-101.SCH 3 grts-20210817.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 grts-20210817_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 grts-20210817_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g111789g0817061340447.jpg GRAPHIC begin 644 g111789g0817061340447.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#WZBBB@ HJ MO=WUK8PR2W,RHL2&1^Y"CJ<#G%43XBL!<^1ND+^>D&0O&77,44?7(.?2K$6O:7*F];R,+Y;R MY?*@(K;2W/;/&:;I36Z$JU-[21I44U71_N,K< \'UIU0:!1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !6?JNI+I\*JC0&[ER+>&:7RQ*PZ MC/KBM"N.\23RO>31R"Z6V "M'=:?Y]K)[@K\RGGK[5K1@ISLS&O4<(71E37, M\]V9 [^?"Y*M=KB2U+?>BG'\4#= XX'%6H-%;RAA738H2-96P4"MOC4^I1QM MSW5P:70X$N"LBLKB/A D_F^6.FU6/[Q5/=75EKL[>UC@0?*"V!DXZ?2NJK5Y M/=1Q4*'M/>E_7]?UV.3_ +&CC?="(_D8&,;C_"TS)^KI4?\ 8BQJ$2)9(U$8 M"&3Y76,?NU;/1(?$#W&I:AJ :5F:Y=5@^8@(BJ0%"XQZUQG<>E45 MYAX"\.6"ZWXJM'DN[J.SN&LHYI+N0YB= 60_-C'M,^W72NR&:.%43&YF=PH S]<_0&N"\3Z =%T? MP8\ES,^H6E]9V+SQS.JR)DYRN<')'?FK'Q=T6RNM*L=1F24W*7MO;J1,P4(T MF&^4'&<$\XS[T"N>D45SL'ARV\,Z3JDN@0SF\DMV,:S7$DVYU5M@ '=$N-5 MNU9HH ,HF-S$D 9[Y-:5>7?$?PY%%\-;6;4)9+G4=.BMX!,)GVLQ=%9MN<$ MGGD\\UTLFDZ1X#T35M;L(;C?#:,[+-=22AMH) PS''/<4!1S&H9(]8\1>!M2NKF^L8(HYK62 M65O-$,@.4+@@_*1P&%(HD.-Y52,LQRWB>1G=-PPSM*XZGHTJC/X5U5IKLK>_1HP)#R.-PY!YQV]_PSGTIXB#YKH6%J)PLR[4%S9)))]T*N7?C/ XQQSU!QG!!4@Q3H MN3-*M>,$:-]J.Q!^\949@-_FRQAF/0!T0@_G6MI-@ULC7$XD6ZE $BM=/,% MZ %O\*J:)HCVLGVV\V_:R,!4/" ]02,;S[L,UNTZDTO=B*E"3?/,;(S)$[JA M=E4D(#RQ]*\&\.7>ER6-U=7C>+-/DN[J:2:'1HI!:IEC\@V @X[D8YKV[5[* M34M%OK&*8P27-N\2RC^ LI /X9KBM!NO&7AO1+/1F\&P7:V<8A2>TU"-$<#C M=M89!/4U@;,TO"&M>$+?1;FTT"1HXK%3-

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end XML 7 d111789d8k_htm.xml IDEA: XBRL DOCUMENT 0001656634 2021-08-17 2021-08-17 false 0001656634 8-K 2021-08-17 Gritstone bio, Inc. DE 001-38663 47-4859534 5959 Horton Street Suite 300 Emeryville CA 94608 (510) 871-6100 false false false false Common Stock, par value $0.0001 GRTS NASDAQ true true XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 17, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001656634
Document Type 8-K
Document Period End Date Aug. 17, 2021
Entity Registrant Name Gritstone bio, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38663
Entity Tax Identification Number 47-4859534
Entity Address, Address Line One 5959 Horton Street
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Emeryville
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94608
City Area Code (510)
Local Phone Number 871-6100
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001
Trading Symbol GRTS
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X9 M9K>]9!:GH_ 0 / ( \ !X;"]W M;W)K8F]O:RYX;6R-49:EL@9OTDUL(,BDBN0- M2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743&4K&& 3L@!W".?W.NU:=,.$> M'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK.%7HR#'9 C.4?>-N)_#3[ MU"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/73>TFH M=>Y!L/?P&HT=S8\?M_P!4$L#!!0 ( \X$5,D'INBK0 /@! : M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q= M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " /.!%399!YDAD! #/ P M$P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M= M< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4' M3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!- MFI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXP MC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T, M:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( M \X$5,'04UB@0 +$ 0 " 0 !D;V-0&UL4$L! A0#% @ #S@14S?F"TGM *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ #S@14YE5T$ !Q$0 & @($," M>&PO=V]R:W-H965T&UL4$L! A0#% @ #S@14Y^@&_"Q M @ X@P T ( !GPP 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ #S@14R0>FZ*M M^ $ !H ( !T!$ 'AL+U]R96QS+W=O9(9 0 SP, !, ( ! MM1( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ @ _Q, end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d111789d8k.htm d111789dex991.htm grts-20210817.xsd grts-20210817_lab.xml grts-20210817_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d111789d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d111789d8k.htm" ] }, "labelLink": { "local": [ "grts-20210817_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "grts-20210817_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "grts-20210817.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "grts", "nsuri": "http://www.gritstoneoncology.com/20210817", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d111789d8k.htm", "contextRef": "duration_2021-08-17_to_2021-08-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d111789d8k.htm", "contextRef": "duration_2021-08-17_to_2021-08-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.gritstoneoncology.com//20210817/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001193125-21-248344-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-248344-xbrl.zip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